Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus ISOPAQUE 440.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus ISOPAQUE 440.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs ISOPAQUE 440
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
Iodinated radiocontrast agent that attenuates X-rays by increasing the iodine content in tissues, providing enhanced visualization of vasculature and organs during imaging procedures.
Intravenous: 0.5-2 mL/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 mL/kg (1850 mg iodine/kg) within a 24-hour period.
Intravenous: 50-100 mL (22.05-44.1 g iodine) as a single dose for CT imaging; intra-arterial: 5-80 mL (2.2-35.28 g iodine) depending on procedure; dose is based on imaging requirements and patient weight.
None Documented
None Documented
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. May be prolonged in renal impairment, correlating with creatinine clearance; dose adjustment not typically required for diagnostic procedures.
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via biliary/fecal routes.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent